Pharmacokinetics, Safety, and Tolerance of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults

Rachel Courtney,* Sudhakar Pai, Mark Laughlin, Josephine Lim, and Vijay Batra

Schering-Plough Research Institute, Kenilworth, New Jersey

Received 16 October 2002/Returned for modification 23 December 2002/Accepted 5 June 2003

The pharmacokinetics, safety, and tolerability of posaconazole, an investigational triazole antifungal, were evaluated following the administration of rising single and multiple oral doses. A total of 103 healthy adults were enrolled in two phase I trials. Each study had a double-blind, placebo-controlled, parallel-group design with a rising single-dose (RSD) or rising multiple-dose (RMD) scheme. In the RSD study, subjects received single doses of posaconazole oral tablets (50 to 1,200 mg) or placebo. In the RMD study, subjects received posaconazole oral tablets (50 to 400 mg) or placebo twice daily for 14 days. By using model-independent methods, the area under the plasma concentration-time curve and the maximum concentration in plasma were determined and used to assess dose proportionality. In the RSD study, the levels of posaconazole in plasma increased proportionally between the 50- and 800-mg dose range, with saturation of absorption occurring above 800 mg. Dose proportionality was also observed in the RMD study. In both studies, the apparent volume of distribution was large (range, 343 to 1,341 liters) and the terminal-phase half-life was long (range, 25 to 31 h). Posaconazole was well tolerated at all dose levels, and the adverse events were not dose dependent. No clinically significant changes in clinical laboratory test values or electrocardiograms were observed. Following the administration of single and twice-daily rising doses, the level of posaconazole exposure increased in a dose-proportional manner. The long elimination-phase half-life of posaconazole supports once- or twice-daily dosing in clinical trials; however, additional studies are required to determine if further division of the dose will enhance exposure.

The evolution of oral triazole antifungal agents began in the 1980s with the introduction of fluconazole and itraconazole for the treatment of systemic fungal infections. In recent years, the patterns of Candida infections have changed. Previously, Candida albicans was the most prevalent cause of Candida infections, whereas in recent times, other Candida species, such as C. glabrata and C. krusei, have become common infection-causing pathogens (6). In addition to this shift in species, fluconazole- and itraconazole-resistant Candida strains have emerged, prompting clinicians to search for alternative treatment options. The emergence of new fungal diseases caused by fungi that were previously not thought to be pathogenic has also limited the usefulness of older triazole compounds for the treatment of invasive infections, especially in immunocompromised patients. For example, fusariosis and zygomycosis are increasingly common; however, the treatments for these infections are limited (23). In light of the need for more potent and broad-spectrum therapeutic options, posaconazole (SCH 56592), a novel oral triazole derivative structurally similar to itraconazole (Fig. 1), is in development for the treatment of invasive fungal infections.

Posaconazole has enhanced activity against many old, new, and emerging fungal pathogens (A. Espinel-Ingroff and A. Rezusta, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. 375, 2001) compared with the activities of the other azoles and caspofungin (an echinocandin). Numerous in vitro studies demonstrate that posaconazole has a broad spectrum of activity against the majority of yeasts, filamentous fungi, and azole-resistant Candida species (1, 3, 14, 18, 19). In addition, posaconazole has excellent in vitro activity against rare and emerging opportunistic fungal pathogens (4, 9, 10, 15, 17), including the difficult-to-treat zygomycetes (21). In a neutropenic mouse model of zygomycosis, posaconazole was shown to significantly reduce the fungal burden in tissue and prolong the survival of mice (22). Compared with fluconazole, which generally demonstrates fungistatic activity (11), in vitro (7) and in vivo (A. H. Groll, D. Mickiene, R. Petraitiene, V. Petraitis, T. Sein, J. Roach, K. Roth, S. C. Piscitelli, and T. J. Walsh, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 385, 2000) evidence suggests that posaconazole is fungicidal against many fungal species. For example, in a neutropenic rabbit model of invasive Aspergillus infection, posaconazole therapy eradicated organisms from tissues, also indicating fungicidal activity (Groll et al., 40th ICAAC).

The pharmacokinetics of oral posaconazole have been evaluated in mice, rats, rabbits, dogs, and cynomolgus monkeys (16). A posaconazole suspension was orally bioavailable in all species; following oral administration of a suspension or solution, absolute bioavailability was approximately 50 to 60% in rats and dogs. The terminal-phase half-life (t1/2) of posaconazole ranged from 7 to 9 h in mice, rats, and rabbits and was 15 and 23 h in dogs and monkeys, respectively. Dose-related increases were observed in mice (dose range, 20 to 160 mg/kg of body weight), rats (10 to 120 mg/kg), and fed dogs (10 to 120 mg/kg) following administration of a single oral dose; however, posaconazole absorption was saturated at higher doses (>80 mg/kg). The posaconazole exposure in dogs was approximately 3.5-fold greater when posaconazole was administered with food. In the fed dog, multiple doses (8 days) resulted in drug
The studies described here are the first to evaluate the pharmacokinetics, safety, and tolerability of oral posaconazole in humans. We summarize herein two independent studies conducted with healthy volunteers that evaluated the single- and multiple-dose pharmacokinetics, safety, and tolerability of posaconazole oral tablets following the administration of escalating oral doses.

### MATERIALS AND METHODS

The studies were conducted in accordance with the Declaration of Helsinki and were approved by an accredited institutional review board. All study participants gave written informed consent.

**Study subjects.** Adult male volunteers aged 18 to 44 (rising single-dose [RSD] study) and adult male and female volunteers aged 19 to 43 (rising multiple-dose [RMD] study) who were in good health on the basis of medical history, physical examination, electrocardiograms (ECGs), and routine laboratory tests and whose weights were within 15% of their ideal body weights on the basis of gravity and creatinine, testosterone levels, and renal function (urine specific gravity and creatinine, sodium, potassium, calcium, N-acetylcysteaminidase, and β2-microglobulin levels). Volunteers were continuously observed and questioned during the period of confinement for the possible occurrence of adverse events. The investigator(s) assessed the intensity (mild, moderate, severe, or life-threatening) of each adverse event and its relationship to the study drug.
RESULTS

All 54 subjects enrolled in the RSD study completed the study; 36 subjects received posaconazole and 18 received placebo. In the RMD study, 48 of the 49 subjects enrolled completed the study; 37 subjects received posaconazole and 12 received placebo. One subject in the group receiving posaconazole at 200 mg BID prematurely discontinued treatment because of an adverse event determined to be unrelated to study drug (a dental abscess requiring antibiotic treatment). In the active treatment and placebo treatment groups in both the RSD and the RMD studies, subjects were similar with respect to age, weight, and height distribution (Table 1). The mean ages and weights of the study subjects were 23 years (range, 18 to 44 years) and 77 kg (range, 53.6 to 103 kg), respectively, in the RSD study and 25 years (range, 19 to 43 years) and 75 kg (range, 51 to 100 kg), respectively, in the RMD study.

Pharmacokinetic findings. The pharmacokinetic analyses included data for 36 subjects in the RSD study and 36 subjects in the RMD study.

(i) RSD study. The mean plasma posaconazole concentration-time profiles at each dose level are shown in Fig. 2. Posaconazole was well absorbed following oral administration, with mean $T_{\text{max}}$ ranging from 5.8 to 8.8 h across the 50- to 1,200-mg dose range (Table 2). Mean posaconazole $C_{\text{max}}$s ranged from 113 to 1,320 ng/ml for doses between 50 and 800 mg. The plasma posaconazole concentrations increased proportionally (defined as $P > 0.05$) between the 50- and 800-mg dose range, with no pairwise statistically significant differences ($P > 0.233$) among the 50- to 800-mg doses for AUC by use of the log-transformed dose-adjusted data (Fig. 2). $C_{\text{max}}$s were also dose proportional ($P > 0.05$) except for doses from 100 to 400 mg ($P = 0.018$), presumably due to variability. The plasma posaconazole concentrations at the 1,200-mg dose level were equal to or lower than those at the 800-mg dose level, suggesting saturation of absorption above the 800-mg dose (Table 2; Fig. 2).

Posaconazole demonstrated dose-independent clearance, with mean $CL/F$ values ranging from 4.1 to 6.6 ml/min/kg across all doses administered. The mean $t_{1/2}$ of posaconazole was approximately 25 h for doses ranging from 200 to 1,200 mg. However, a faster rate of elimination was observed at the lower doses of 50 and 100 mg, with mean $t_{1/2}$s of 16 and 18 h, respectively. The mean apparent $V/F$ of posaconazole was large (range, 431 to 1,341 liters), indicating extensive distribution in tissues.

(ii) RMD study. On day 1, mean $C_{\text{max}}$s following the administration of the first dose were achieved at 5 h postdosing for all posaconazole dose levels, after which the plasma posaconazole concentrations slowly declined for up to 16 h postdosing (Fig. 3). On day 1, mean $C_{\text{max}}$s following administration of the

![FIG. 2. Mean concentrations of posaconazole in plasma over time after administration of a single dose.](http://aac.asm.org/)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>RSD study</th>
<th>RMD study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Posaconazole ($n = 36$)</td>
<td>Placebo ($n = 18$)</td>
</tr>
<tr>
<td>Age (yr)</td>
<td>22.7 (18–44)</td>
<td>22.8 (18–41)</td>
</tr>
<tr>
<td>Wt (kg)</td>
<td>78.1 (53.6–103)</td>
<td>75.3 (57.2–101)</td>
</tr>
<tr>
<td>Ht (cm)</td>
<td>184.8 (170–199)</td>
<td>183.2 (174–200)</td>
</tr>
</tbody>
</table>

a One subject did not complete the treatment, and the data for that subject are not included.

b The values are presented as means (ranges).
second dose were attained by approximately 8 h after the administration of the second dose (at ~20 h after the administration of the first dose) and did not decline appreciably thereafter, suggesting that accumulation of the drug occurred with repeated daily dosing (Fig. 3).

Steady-state concentrations were achieved by day 10 of dosing (the first sample collected for evaluation of $C_{\text{min}}$), with no statistically significant increase in $C_{\text{min}}$ observed between days 10 and 14 ($P > 0.155$). The plasma posaconazole pharmacokinetic parameters after 14 days of multiple twice-daily dosing are summarized in Table 3. On day 14, peak concentrations were attained from 4 to 6 h after the administration of the morning dose and from 9 to 11 h after the administration of the evening dose. Following the administration of the final dose on day 14, quantifiable concentrations in plasma were detected for up to 120 h postdosing for all dose levels (Fig. 4). Posaconazole exhibited dose-proportional increases in exposure ($\text{AUC}_{0-12}$ and $\text{AUC}_{12-24}$) on day 1 (for $\text{AUC}_{0-12}$, $P = 0.138$; for $\text{AUC}_{12-24}$, $P = 0.073$) and at steady state (day 14) (for $\text{AUC}_{0-12}$, $P = 0.197$; for $\text{AUC}_{12-24}$, $P = 0.148$). The $C_{\text{max}}$ after the administration of the morning dose was dose proportional on day 1 and at steady state ($P = 0.085$ and $P = 0.246$, respectively), but the $C_{\text{max}}$ after the administration of the second daily dose was not dose proportional (for day 1, $P = 0.030$; for steady state, $P = 0.044$). Figure 5 shows the concentration-time profile of posaconazole following twice-daily dosing for 14 days.

Over the 50- to 400-mg BID dose range, the mean $t_{1/2}$ (range, 19 to 31 h) and mean apparent $V/F$ (range, 343 to 486 liters) were similar to those observed in the RSD study. The accumulation values based on $\text{AUC}_{0-12}$ ratios ($\text{AUC}_{0-12}$ on day 14/$\text{AUC}_{0-12}$ on day 1) were between 6.6- and 8.3-fold (Table 3).

**Safety and tolerability.** The safety analyses included data for 54 subjects in the RSD study and 49 subjects in the RMD study. Posaconazole was well tolerated in both studies. No subjects reported serious adverse events or discontinued the studies prematurely because of drug-related adverse events. However, in the RMD study, one subject assigned to posaconazole treatment discontinued early because of a severe dental abscess determined to be unrelated to the study medication.

(i) **RSD study.** Of the 54 subjects enrolled in the RSD study, 27 (50%; 18 posaconazole-treated subjects and 9 placebo-treated subjects) reported at least one adverse event. The overall incidence of adverse events among subjects receiving

---

**TABLE 2. Pharmacokinetic parameters for posaconazole in plasma after administration of a single dose (RSD study)**

<table>
<thead>
<tr>
<th>Posaconazole dose (mg)</th>
<th>$C_{\text{max}}$ (ng/ml)</th>
<th>$T_{\text{max}}$ (h)</th>
<th>$\text{AUC}_{0} \cdot \text{h/ml}$</th>
<th>$\text{AUC}_{1} \cdot \text{h/ml}$</th>
<th>$t_{1/2}$ (h)</th>
<th>$\text{CL/F}$ (ml/min)</th>
<th>$V/F$ (liters)</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>113 (46)$^b$</td>
<td>6.3 (51)</td>
<td>2,317 (50)</td>
<td>2,501 (45)</td>
<td>15.9 (18)</td>
<td>389 (40)</td>
<td>511 (32)</td>
</tr>
<tr>
<td>100</td>
<td>235 (26)</td>
<td>7.3 (36)</td>
<td>6,101 (28)</td>
<td>6,357 (27)</td>
<td>18.3 (13)</td>
<td>275 (21)</td>
<td>431 (20)</td>
</tr>
<tr>
<td>200</td>
<td>332 (21)</td>
<td>5.8 (35)</td>
<td>10,354 (30)</td>
<td>10,869 (31)</td>
<td>24.5 (22)</td>
<td>341 (40)</td>
<td>674 (18)</td>
</tr>
<tr>
<td>400</td>
<td>611 (31)</td>
<td>6.3 (44)</td>
<td>19,401 (33)</td>
<td>20,264 (33)</td>
<td>24.1 (24)</td>
<td>363 (35)</td>
<td>781 (49)</td>
</tr>
<tr>
<td>800</td>
<td>1,320 (26)</td>
<td>6.2 (46)</td>
<td>46,984 (40)</td>
<td>49,841 (43)</td>
<td>24.4 (33)</td>
<td>320 (48)</td>
<td>594 (19)</td>
</tr>
<tr>
<td>1,200</td>
<td>933 (28)</td>
<td>8.8 (85)</td>
<td>41,755 (42)</td>
<td>45,260 (44)</td>
<td>28.5 (26)</td>
<td>585 (73)</td>
<td>1,341 (58)</td>
</tr>
</tbody>
</table>

$^a$ Each dose group contained six subjects.

$^b$ The values in parentheses are CVs (in percent).
posaconazole was identical to that among subjects in the placebo group (50% in each group). The incidence of any of the adverse events did not increase with increasing dose. Regardless of causality, the most common adverse events (which occurred in \( \geq 10\% \) of subjects) reported among those receiving posaconazole were headache, somnolence, dizziness, and fatigue. The types of adverse events were similar between the posaconazole- and placebo-treated groups; however, only subjects receiving posaconazole reported fatigue (overall incidence, 11%).

(ii) RMD study. Of the 49 subjects enrolled in the RMD study, 42 (86%; 31 posaconazole-treated subjects and 11 placebo-treated subjects) reported at least one adverse event. The majority of the adverse events were mild and of short duration (<12 h); eight adverse events were rated as moderate, with only headache being possibly related to study drug administration. The single previously mentioned non-drug-related adverse event (a dental abscess) was rated as severe. The overall incidence of adverse events among subjects receiving posaconazole was lower than that observed among the subjects in the RMD study (posaconazole-treated group, 84%; placebo-treated group, 92%). In general, the types of adverse events were similar between the posaconazole- and placebo-treated groups. In contrast to the RSD study, fatigue was reported more frequently by the placebo-treated subjects (25%) than by the posaconazole-treated subjects (14%). Regardless of causality, the most common adverse events (occurring in \( \geq 10\% \) of the subjects) reported by the posaconazole-treated subjects were headache, dry mouth, somnolence, dizziness, fatigue, and constipation. Although a larger number of subjects receiving the higher doses of posaconazole reported dry mouth (\( n = 0 \) in the 50-mg BID group; \( n = 1 \) in the 100-mg BID group; \( n = 3 \) in the 200-mg BID group; \( n = 8 \) in the 400-mg BID group), subjects administered placebo (\( n = 2 \)) also reported this event.

### Laboratory safety tests, vital signs, and ECG results
No consistent or clinically significant changes in baseline values were observed by routine or special laboratory safety tests (tests for serum cortisol and testosterone levels) in either study, although there was a trend toward reduced testosterone levels at day 14 in those treated with higher doses of posaconazole. In the RSD study, there were no clinically significant differences between the posaconazole- and placebo-treated groups.

### Pharmacokinetic parameters for posaconazole in plasma on day 14 after BID dosing (RMD study)

<table>
<thead>
<tr>
<th>Posaconazole dose (mg)</th>
<th>C&lt;sub&gt;max1&lt;/sub&gt; (ng/ml)</th>
<th>T&lt;sub&gt;max1&lt;/sub&gt; (h)</th>
<th>C&lt;sub&gt;max2&lt;/sub&gt; (ng/ml)</th>
<th>T&lt;sub&gt;max2&lt;/sub&gt; (h)</th>
<th>AUC&lt;sub&gt;0-12&lt;/sub&gt; (ng·h/ml)</th>
<th>AUC&lt;sub&gt;12-24&lt;/sub&gt; (ng·h/ml)</th>
<th>AUC&lt;sub&gt;0-24&lt;/sub&gt; (ng·h/ml)</th>
<th>t&lt;sub&gt;1/2&lt;/sub&gt; (h)</th>
<th>CL/F (liters/h)</th>
<th>V/F (liters)</th>
<th>Accumulation ratio&lt;sup&gt;cd&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>457 (38)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5 (12)</td>
<td>371 (30)</td>
<td>9 (34)</td>
<td>4,454 (37)</td>
<td>3,841 (36)</td>
<td>8,295 (36)</td>
<td>19.2 (16)</td>
<td>13.5 (34)</td>
<td>365 (29)</td>
<td>6.6 (29)</td>
</tr>
<tr>
<td>100</td>
<td>1,141 (37)</td>
<td>6 (40)</td>
<td>1,045 (42)</td>
<td>11 (16)</td>
<td>11,571 (40)</td>
<td>10,206 (40)</td>
<td>21,778 (40)</td>
<td>24.1 (21)</td>
<td>10.3 (32)</td>
<td>343 (24)</td>
<td>6.9 (27)</td>
</tr>
<tr>
<td>200</td>
<td>1,753 (27)</td>
<td>4 (12)</td>
<td>1,358 (27)</td>
<td>10 (19)</td>
<td>16,801 (26)</td>
<td>14,305 (27)</td>
<td>31,106 (26)</td>
<td>23.9 (26)</td>
<td>13.9 (34)</td>
<td>467 (32)</td>
<td>7.6 (37)</td>
</tr>
<tr>
<td>400</td>
<td>4,150 (20)</td>
<td>5 (12)</td>
<td>3,239 (19)</td>
<td>9 (32)</td>
<td>39,206 (20)</td>
<td>33,899 (21)</td>
<td>73,105 (20)</td>
<td>31.0 (46)</td>
<td>11.5 (25)</td>
<td>486 (34)</td>
<td>8.3 (32)</td>
</tr>
</tbody>
</table>

<sup>a</sup>C<sub>max1</sub> and T<sub>max1</sub>, values after the administration of the first dose; C<sub>max2</sub> and T<sub>max2</sub>, values after the administration of the second dose.

<sup>b</sup>Each dose group contained nine subjects.

<sup>c</sup>Accumulation ratio, AUC<sub>0-12</sub> on day 14 to AUC<sub>0-12</sub> on day 1.

<sup>d</sup>The values in parentheses are CVs (percent).

---

**FIG. 4.** Mean concentration of posaconazole in plasma by dose on day 14 of twice-daily administration.
groups in the results of special urine tests. A few isolated cases of elevated alanine aminotransferase levels, either with or without accompanying increases in the levels of other liver enzymes (aspartate aminotransferase and \(\gamma\)-glutamyltransferase), were observed in both studies. These elevations were mild to moderate and were observed in subjects administered placebo \((n = 2)\) as well as those administered posaconazole \((n = 3)\). Two subjects (one in the placebo-treated group and one in the 400-mg BID dose group) had World Health Organization grade 2 increases in alanine aminotransferase levels. The changes in liver enzyme levels in all subjects with increased levels returned to the baseline levels within 2 weeks of the completion of treatment.

No clinically relevant changes in vital signs were observed in the posaconazole-treated subjects in either the RSD study or the RMD study. Similarly, there were no clinically relevant changes in ECG results for posaconazole-treated subjects (in both the RSD study and the RMD study) in comparison with their baseline values or compared with those for the placebo-treated subjects. Two subjects who received single 100- or 200-mg doses (RSD study) had mild transient prolongation of their corrected QT interval (<10% above the baseline); however, these changes were considered to be within normal diurnal variation and not clinically relevant.

**DISCUSSION**

The studies described here are the first to evaluate the pharmacokinetics, safety, and tolerability of oral posaconazole in humans following the administration of increasing single and multiple doses. In both studies, posaconazole was found to be orally bioavailable and slowly eliminated and displayed dose-proportional (AUC) pharmacokinetics up to a total dose of 800 mg/day. No further increases in concentrations in plasma were observed with the 1,200-mg dose, suggesting that absorption was saturated above 800 mg. It is unknown why this saturation occurred, but it is primarily thought to be due to the poor solubility of posaconazole (pK\(_a\) = 8; melting range = 164 to 165°C).

Because the saturation of absorption was observed at doses greater than 800 mg, we hypothesized that splitting the dose may increase the total amount of drug absorbed. Thus, we designed and conducted the RMD study. Data from these two trials indicate that posaconazole has an extensive V/F; approximately 10-fold greater than that of total body water (~42 liters), indicating that posaconazole is widely distributed into tissues. Similar estimates of \(t_{1/2}\) of 25 h were observed in the RSD and RMD studies. On the basis of this \(t_{1/2}\), the predicted level of accumulation following BID dosing is fourfold. However, accumulation, expressed as the ratio of the AUC₀₋₁₂ on day 14 to the AUC₀₋₁₂ on day 1, was six- to eightfold in the RMD study. The reason for the difference in accumulation between the actual and predicted values upon multiple dosing is unknown.

Following the administration of all dose levels in both studies, posaconazole was slowly eliminated with a long \(t_{1/2}\), typically ranging from 25 h following the administration of a single dose and up to 31 h following the administration of multiple doses. This implies that twice-daily dosing would be an appropriate clinical dosage regimen for the treatment of serious fungal infections; however, additional studies are required to determine if further division of the dose would enhance exposure.

The results from these studies of the pharmacokinetics of posaconazole in humans corroborate those findings reported from preclinical investigations with animals, in which dose-related increases in exposure were observed in all species, although a saturation of absorption was observed at higher
doses (16). Similar to humans, \( t_{1/2} \)s were prolonged in dogs and monkeys (15 and 23 h, respectively), and as in the multiple-dose study with humans, significant accumulation was detected in all animal species evaluated following multiple once-daily oral dosing.

The pharmacokinetic properties of the currently marketed azole and triazole antifungal agents vary greatly. It is well recognized that the capsule formulation of itraconazole is associated with highly erratic absorption and unpredictable concentrations in plasma (5, 12). However, the itraconazole solution appears to have more reliable pharmacokinetics (5) when it is given on an empty stomach (2). In comparison with posaconazole, fluconazole has a less variable pharmacokinetic profile (i.e., food does not affect its bioavailability); however, fluconazole has reduced microbiological activity against some non-albicans Candida species and no activity against Aspergillus species and some rare fungi (18). The pharmacokinetics of voriconazole, a new triazole, have been described recently (20). In contrast to posaconazole, voriconazole exhibits non-linear pharmacokinetics when it is administered at the recommended clinical doses (i.e., disproportional increases in \( C_{\text{max}} \) and AUC with increasing dose), possibly due to saturable first-pass metabolism. Furthermore, the interindividual variability of voriconazole pharmacokinetics is high (AUC variability range, 74 to 100%, depending on the dose and the route of elimination), and the mean \( t_{1/2} \) of voriconazole (6 to 12 h) is shorter than that of posaconazole (13).

Posaconazole was well tolerated in both the single-dose and the multiple-dose trials. The most commonly reported adverse events were mild to moderate and nonspecific and included headache, somnolence, dizziness, and fatigue. There also was no suggestion that posaconazole caused cardiac adverse events, including clinically significant ECG findings or QT prolongation. Although there were more reports of dry mouth in subjects receiving the higher doses of posaconazole, the rates of adverse events did not appear to be dose dependent over the range of doses studied (i.e., 50- to 1,200-mg single doses and from 50 to 400 mg BID for 14 days). Although this study was a small phase I trial, the safety and tolerability of posaconazole will ultimately be determined in large phase III clinical trials and by postmarketing surveillance.

Although the present studies were small and conducted with healthy subjects, the findings suggest that posaconazole may have a clinical safety and tolerability advantage over other antifungal agents. Amphotericin B and fluconazole are associated with renal and hematologic toxicities. Voriconazole has been associated with ocular toxicity, elevated liver enzyme levels by liver function tests (LFTs), and rash (13; VFEND package insert; Pfizer Inc., 2002). Visual disturbances following voriconazole administration are significant, with approximately 30% of subjects experiencing altered or enhanced visual perception, blurred vision, color vision change, and/or photophobia (13; VFEND package insert; Pfizer Inc., 2002). In addition, LFT abnormalities with voriconazole appear to be directly related to increased doses (K. K. C. Tan, N. Brayshaw, and M. Oakes, Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-18, 2001). Following 14 days of dosing with posaconazole, there was no evidence that posaconazole was associated with nephrotoxicity, hepatotoxicity, skin reactions, or visual toxicity. Although LFT abnormalities were reported, the number of reports was very small and the frequencies were similar between the placebo groups and the treatment groups. Thus, it is impossible to distinguish the reason for these elevations. Posaconazole may prove to be a better-tolerated alternative to some currently available antifungals if this lack of toxicity is confirmed in ongoing clinical trials.

In conclusion, posaconazole was well tolerated by healthy human adults following the administration of single oral doses and multiple twice-daily doses. Posaconazole was orally bioavailable, demonstrated dose-proportional pharmacokinetics, and was characterized by a large \( V/F \). The long \( t_{1/2} \) observed with posaconazole supports once- or twice-daily dosing in clinical trials; however, additional studies are required to determine if divided dosing will further enhance the exposure to posaconazole.

REFERENCES


